Core Viewpoint - Meihua International Medical Technologies Co., Ltd. is facing delisting from Nasdaq due to non-compliance with listing rules, specifically failing to maintain a minimum bid price and the required number of publicly held shares [1][5]. Group 1: Delisting Details - On December 2, 2025, Nasdaq notified Meihua of the delisting determination due to failure to regain compliance with Listing Rule 5550(a)(2) [1]. - The company was previously informed on December 3, 2024, that its share price had been below $1 for 30 consecutive business days, violating Listing Rule 5450(a)(1) [2]. - Meihua executed a reverse share split of 1:16 on November 24, 2025, but did not meet the $1.00 minimum bid price requirement for 10 consecutive business days before December 1, 2025 [3]. Group 2: Compliance and Appeal - The company was given until December 9, 2025, to appeal the delisting decision, and it submitted a hearing request on December 4, 2025 [4]. - As of December 1, 2025, Meihua was also found to have less than 500,000 publicly held shares, which is another basis for delisting under Listing Rule 5550(a)(4) [5]. Group 3: Company Overview - Meihua International Medical Technologies Co., Ltd. manufactures and provides Class I, II, and III disposable medical devices, with over 1,000 types of products for domestic sales and more than 120 products exported to over 30 countries [6]. - The company has received international "CE" certification and ISO 13485 system certification, and is registered with the FDA for over 20 Class I products [6].

Core Points - Meihua International Medical Technologies Co., Ltd. announced a reverse share split at a ratio of 1-for-100, effective November 24, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2][4] Group 1: Reverse Share Split Details - The reverse share split will change the par value of Class A ordinary shares from $0.0005 to $0.05 per share [2] - The number of issued and outstanding Class A ordinary shares will decrease from approximately 56 million to approximately 0.56 million [4] - No fractional shares will be issued; fractional interests will be rounded up to the nearest whole number [3] Group 2: Shareholder Information - VStock Transfer, LLC is designated as the exchange agent and will provide instructions to shareholders regarding the exchange of share certificates [5][6] - Shareholders holding shares in book-entry form or brokerage accounts do not need to take any action for the reverse share split [5] Group 3: Company Overview - Meihua is a manufacturer of Class I, II, and III disposable medical devices, with over 1,000 products for domestic sales and more than 120 products exported to over 30 countries [7] - The company has received international "CE" certification and ISO 13485 system certification, and is registered with the FDA for over 20 Class I products [7]

Financial Performance - Revenues for the fiscal year 2024 were approximately $96.91 million, a slight decrease of 0.2% from $97.10 million in 2023 [3][9][10] - Gross profit increased by 0.3% to approximately $33.30 million, maintaining a gross margin of 34% for both years [3][12] - Income from operations decreased by 2.5% to approximately $14.31 million, while net income attributable to shareholders fell by 6.5% to approximately $10.84 million [3][19][21] Strategic Initiatives - The company focused on transitioning towards high-end medical products and enhancing operational efficiency, resulting in a stable revenue performance despite macroeconomic challenges [5] - A significant transformation included the sale of a controlling equity stake in Hainan Guoxie, reallocating capital towards higher-growth opportunities [6][22] - The construction of an integrated medical industrial park in Boao Hope City is underway, expected to be completed by mid-2025, aimed at consolidating R&D, manufacturing, and commercialization [6] Innovation and Technology - The launch of the AI-powered Speed Fox warehouse management platform in May 2024 improved supply chain efficiency [7] - Participation in a remote robotic lobectomy in July 2024 showcased the company's commitment to surgical innovation [7] - The company plans to expand its high-end medical product portfolio and integrate AI to enhance operational excellence [7]